LICENSE, COLLABORATION AND OTHER REVENUE - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)		3 Months Ended		9 Months Ended
	Jun. 30, 2018 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) performanceObligation	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		$ 42,046,000	$ 48,714,000	$ 138,427,000	$ 236,702,000
Revenue recognized		0	5,047,000	0	29,574,000
Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		480,000	1,870,000	480,000	1,870,000	$ 1,901,000	$ 19,094,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 4,400,000
Mitsubishi Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue		500,000	400,000	1,400,000	1,200,000
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	25,000,000			$ 25,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performanceObligation				2
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	15,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received	20,000,000
Cost of research services	20,500,000
Milestone revenue	10,000,000
Deferred revenue		0		$ 0
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	$ 10,000,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		0		0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		0		0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized		$ 0	$ 5,100,000	$ 3,700,000	$ 12,700,000